We are pleased to announce our collaboration with ConferenceInsider™ to bring you on-site coverage of ASN Kidney Week 2019 from our nation's capital. We'll bring you the heart of ASN Kidney Week 2019, from November 7 - 11, 2019. This is your direct connection to the most trusted and clinically relevant information about recent advances in the...
We are pleased to announce our collaboration with ConferenceInsider™ to bring you on-site coverage of ASN Kidney Week 2019 from our nation's capital. We'll bring you the heart of ASN Kidney Week 2019, from November 7 - 11, 2019. This is your direct connection to the most trusted and clinically relevant information about recent advances in the field of nephrology.
We'll continue to post educational session summaries and interviews with key opinion leaders throughout the conference – delivering the latest developments in nephrology medicine and patient care right to your email inbox. We want to hear from you, too. So be sure to share your opinions through our insightful daily polls.
If you’re not signed up already, please subscribe to UKidney to receive daily emails throughout ASN Kidney Week 2019. Each email will directly link to posted session updates. We hope you enjoy this resource!
Sub-session: Global Kidney Health Atlas: Why We Need It and How It May Affect CKD Worldwide
Presenter: David W. Johnson DrMed, MBBS, PhD, FASN
David W. JohnsonDavid W. Johnson, MBBS, led the session of the global challenges of CKD with his presentation on the Global Kidney Health Atlas (GKHA), why a report like this is needed and how it may impact CKD worldwide.
The GKHA gathers “data [from all over the globe] to determine the status of existing resources, structures and organizations available to patients with CKD and AKI”.
Authors: Sarah M. Azer, Mayo Clinic; Lisa E. Vaughan, MS; Peter Tebben, MD; David J. Sas DO, MPH
This study compared laboratory, imaging, clinical characteristics of patients with suspected or confirmed 24 Hydroxylase (24HD) “to other disorders of vitamin D-mediated hypercalcemia such as, sarcoidosis (S), lymphoma (L), and exogenous vitamin D toxicity (EVT).” Patients with 24 Hydroxylase (24HD) “have clinical and laboratory differences compared to other causes of vitamin D mediated hypercalcemia.” For patients with hypercalcemia who present at a young age, have a positive family history, and have nephrocalcinosis, clinicians should suspect 24HD.
David W. JohnsonDavid W. Johnson, MBBS, led the session of the global challenges of CKD with his presentation on the Global Kidney Health Atlas (GKHA), why a report like this is needed and how it may impact CKD worldwide.